Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Biohaven Pharmaceutical Holding Company Ltd
Cash from Financing Activities
Biohaven Pharmaceutical Holding Company Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
|
Cash from Financing Activities
$211.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Biohaven Pharmaceutical Holding Company Ltd's Cash from Financing Activities?
Cash from Financing Activities
211.9m
USD
Based on the financial report for Dec 31, 2023, Biohaven Pharmaceutical Holding Company Ltd's Cash from Financing Activities amounts to 211.9m USD.
What is Biohaven Pharmaceutical Holding Company Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
12%
Over the last year, the Cash from Financing Activities growth was -72%. The average annual Cash from Financing Activities growth rates for Biohaven Pharmaceutical Holding Company Ltd have been 12% over the past three years .